Monitor the post-split trading price to confirm Nasdaq compliance; the company's forward-looking statements note a need for significant additional financing with no commitments in place.
Price Chart
Executive Summary
Moleculin Biotech filed an 8-K to announce a 1-for-20 reverse stock split, effective October 20, 2026, reducing outstanding shares from ~20.91 million to ~1.05 million. The split is a mechanical capital structure adjustment with no new business catalyst, aimed at maintaining Nasdaq listing compliance.
Key Facts
- Reverse stock split ratio: 1-for-20, effective 12:01 a.m. ET on October 20, 2026.
- Outstanding shares reduced from ~20.91 million to ~1.05 million; authorized shares remain at 500 million.
- Stockholder approval obtained at annual meeting on October 9, 2026; board set the ratio at 1:20.
- No fractional shares issued; cash paid in lieu based on 5-day average closing price pre-split.
- Ticker symbol MBRX unchanged; new CUSIP number 60855D507.
- Proportionate adjustments to stock options, RSUs, warrants, and equity plan shares.
Financial Impact
No new capital raised or business impact; reverse split is a mechanical share consolidation to meet Nasdaq minimum bid price requirement.
Risk Factors
- Post-split stock price may not sustain Nasdaq minimum bid price compliance.
- Company explicitly requires significant additional financing with no committed sources.
- No new clinical or business catalysts announced alongside the split.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032969 |
| Exhibit: ex_1026361.htm | 0001437749-26-032969 |
| Exhibit: ex_1026647.htm | 0001437749-26-032969 |
| Document: 0001437749-26-032969-index-headers.html | 0001437749-26-032969 |
| Document: 0001437749-26-032969-index.html | 0001437749-26-032969 |
| Document: 0001437749-26-032969.txt | 0001437749-26-032969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers